Lightnews — Scholar-powered news

Daniel S. Levine @dslevine.bsky.social · 17h

Arc Institute’s Hani Goodarzi, Ultima Genomics' Gilad Almogy, and 10X Genomics' Serge Saxonov discuss the ARC Virtual Cell Atlas, which uses single-cell genomics, AI, and open science to understand the complexities of cellular behavior.

thebioreport.podbean.com/e/transformi...

Transforming Drug Discovery and Disease Research—One Cell at a Time | The Bio Report

The ARC Virtual Cell Atlas uses high-throughput single-cell genomics, artificial intelligence, and open science to understand the complexities of cellular behavior. Developed through a partnership bet...

thebioreport.podbean.com

Daniel S. Levine @dslevine.bsky.social · 5d

Amélie Lothe, global medical community head for rare epilepsies at UCB, discusses the importance of looking beyond seizures to view developmental and epileptic encephalopathies as complex neurodevelopmental conditions. @globalgenes.bsky.social #RARECast

globalgenes.org/raredaily/th...

The Need to Look Beyond Seizures When Treating DEEs

Amelie Lothe, global medical community head for rare epilepsies at UCB, about the importance of viewing developmental and epileptic encephalopathies as complex neurodevelopmental conditions, the need ...

globalgenes.org

Daniel S. Levine @dslevine.bsky.social · 7d

Marc Salzberg, CEO of Airway Therapeutics, discusses the company’s experimental therapy zelpultide alfa to treat preterm infants with a rare lung disease, why it’s a pipeline-in-a-product, and its development path forward.

thebioreport.podbean.com/e/scratching...

1

Daniel S. Levine @dslevine.bsky.social · 8d

Here's what you may have missed in September from The Bio Report, RARECast, and Life Sciences D'n'A podcasts.

www.linkedin.com/pulse/extend...

Extending the Life of Transplanted Kidneys, Changing the Playbook on Childhood Cancers, and Navigating AI in Clinical Development

Here's what you may have missed in September from The Bio Report, RARECast, and Life Sciences D'n'A podcasts. The Bio Report A Dual Action Approach to Treating MASH MASH, a chronic and progressive for...

www.linkedin.com

1

Daniel S. Levine @dslevine.bsky.social · 12d

Todd Harris, CEO of Tyra Biosciences, discusses the company’s experimental oral medicine for achondroplasia, studies conducted to date, and why he believes it will offer competitive advantages over existing therapies. @globalgenes.bsky.social #RARECast

globalgenes.org/raredaily/ta...

Taking On Big Competitors with an Oral Therapy to Treat Achondroplasia

Todd Harris, CEO of Tyra Biosciences, discusses the company’s experimental once-daily, oral medicine for achondroplasia; what’s known about it from studies conducted to date, and why he believes it wi...

globalgenes.org

1

Daniel S. Levine @dslevine.bsky.social · 13d

What happens when AI touches every role, every day, in clinical development? Stephen Pyke of @parexel.bsky.social, in conversation with Nagaraja Srivatsan, highlights why preparing teams early is essential to unlock their full potential.

trials?https://www.youtube.com/watch?v=gNTNJhLfzT0&t=1s

Daniel S. Levine @dslevine.bsky.social · 14d

Rohan Palekar, CEO of 89bio, discusses what’s driving the prevalence of MASH, the limits of existing medicines, and how the company’s experimental therapy targets both liver fibrosis and the underlying metabolic dysfunctions of the disease.

thebioreport.podbean.com/e/a-dual-act...

1

Daniel S. Levine @dslevine.bsky.social · 19d

Paul Peter Tak, president and CEO of Candel Therapeutics, discusses the company's viral immunotherapy for brain cancer, how it works, and what clinical studies have shown to date. @globalgenes.bsky.social #RARECast

globalgenes.org/raredaily/65...

Going Viral to Fight Brain Cancer

Paul Peter Tak, president and CEO of Candel Therapeutics, discsses its viral immunotherapy, how it works, and what clinical studies have shown to date.

globalgenes.org

1

Daniel S. Levine @dslevine.bsky.social · 21d

Steve Perrin, CSO of Eledon Pharmaceuticals, discusses the need for innovative approaches to immunosuppression in organ transplantation, how its experimental therapy works, and why it may have benefits in autoimmune and neurodegenerative diseases as well.
thebioreport.podbean.com/e/extending-...

1

Daniel S. Levine @dslevine.bsky.social · 26d

David Jenkinson of @lifearc.bsky.social discusses the children’s cancer therapeutics consortium C-Further, the challenges of developing treatments for childhood cancers, and why new models for advancing these therapies are needed. @globalgenes.bsky.social #RARECast

open.spotify.com/episode/13td...

1

Daniel S. Levine @dslevine.bsky.social · 27d

Mohan Uttarwar, CEO of @1Cell.Ai discusses how AI-powered cell biopsy could make cancer monitoring more accessible, minimally invasive, and transformative for millions of patients worldwide

www.agilisium.com/podcast/tran...

Transforming Cancer Diagnostics and Care with AI

Explore how Mohan Uttarwar and Amar Drawid discuss AI-powered cell biopsy, early cancer detection, and the future of precision oncology.

www.agilisium.com

Daniel S. Levine @dslevine.bsky.social · 28d

Greg Mario, CEO of Taxis Pharmaceuticals, discusses the public health threat posed by drug-resistant gonorrhea, the approaches it’s taking to develop new antimicrobial treatments, and the need for new funding models to bring new therapies to market.

thebioreport.podbean.com/e/overcoming...

1

Daniel S. Levine @dslevine.bsky.social · Sep 5

Robin Williams of UofM Masonic Children's Hospital describes the medical mystery of a 15-year-old who became critically ill when he was admitted into a PICU and what it took to diagnose him with the ultra-rare disease TAFRO. @globalgenes.bsky.social #RARECast

globalgenes.org/raredaily/so...

Sometimes the Hoofbeats Do Belong to Zebras

Robin Williams, assistant professor of pediatric hematology/oncology at the University of Minnesota Masonic Children's Hospital, describes the case of Avion, a 15-year-old who became critically ill wh...

globalgenes.org

Daniel S. Levine @dslevine.bsky.social · Sep 3

Marc Hedrick, president and CEO of Plus Therapeutics, Inc., discusses the challenges of treating brain tumors, the limitations of current therapies, and why the company’s targeted radiotherapies have the potential to create better outcomes for patients.

thebioreport.podbean.com/e/using-targ...

Daniel S. Levine @dslevine.bsky.social · Aug 27

Morten Graugaard, co-founder and CEO of Orbis Medicines, discusses its class of synthetic macrocycles, called nCycles, its platform technology for generating and screening these therapies, and how they can offer an orally delivered alternative to biologics.

thebioreport.podbean.com/e/hitting-pr...

1

Daniel S. Levine @dslevine.bsky.social · Aug 22

Tris Dyson, managing director of Challenge Works, discusses his diagnosis of ALS, the case for using a prize to spur innovation, and the potential for leveraging AI to find treatments for the disease. @globalgenes.bsky.social #RARECast

globalgenes.org/raredaily/us...

Using AI Open Innovation to Tackle ALS

Tris Dyson, managing director of Challenge Works, about his diagnosis of ALS, the case for using a prize to spur innovation, and the potential for leveraging AI to find treatments for the disease.

globalgenes.org

1 1

Daniel S. Levine @dslevine.bsky.social · Aug 20

Stacey Adam of the Foundation for the National Institutes of Health, discusses the public-private partnership she is leading to advance alternatives to animal testing, the technologies they are exploring, and their potential to accelerate drug development.

thebioreport.podbean.com/e/building-b...

Daniel S. Levine @dslevine.bsky.social · Aug 15

Daniel Fischer of Tevard Biosciences discusses his journey as the parent of a child with a rare disease, how it led to his co-founding Tevard, and its pursuit of tRNA therapies that may treat a range of diseases with a single drug. @globalgenes.bsky.social #RARECast

globalgenes.org/raredaily/re...

Recovering What’s Lost in Translation

Daniel Fischer, CEO of Tevard Biosciences, discusses his own journey as the parent of a child with the rare epilepsy Dravet syndrome, how it led to his co-founding Tevard and its pursuit of tRNA thera...

globalgenes.org

1

Daniel S. Levine @dslevine.bsky.social · Aug 14

Dimitris K. Agrafiotis, Director of Digital Analytics and AI at Arsenal Capital Partners discusses why AI will have a bigger near-term impact on improving operational overhead than on driving novel science.

www.agilisium.com/podcast/why-...

Dr. Dimitris Agrafiotis – AI & Data Science Leader in Healthcare Innovation

Discover Dr. Dimitris Agrafiotis, a global leader in AI, data science, and healthcare innovation. Renowned for building enterprise-wide solutions, fostering collaboration, and driving digital transfor...

www.agilisium.com

Daniel S. Levine @dslevine.bsky.social · Aug 13

Lorin Johnson of Glycyx discusses the effect of opioids on the immune system and the company’s experimental therapy designed to mitigate the negative effects of opioids in cancer patients being treated with checkpoint inhibitors.

thebioreport.podbean.com/e/preventing...

1

Daniel S. Levine @dslevine.bsky.social · Aug 8

Tien Lee, CEO of Aardvark Therapeutics, discusses Prader-Willi syndrome, the biological difference between hunger and appetite, and why his company’s experimental therapy may have broader applications in other forms of obesity. @globalgenes.bsky.social #RARECast

globalgenes.org/raredaily/ta...

Targeting Hunger Rather than Appetite in Prader-Willi Syndrome

Tien Lee, CEO of Aardvark Therapeutics, discusses Prader-Willi syndrome, the company’s experimental therapy to treat the condition, and why it may have broader applications in other forms of obesity.

globalgenes.org

Daniel S. Levine @dslevine.bsky.social · Aug 6

Abbas Kazimi, CEO Nimbus Therapeutics, discusses how the company’s drug discovery approach has evolved with AI, its deal making successes, and how its business model provides liquidity to investors and while making it easier to structure deals.

thebioreport.podbean.com/e/better-liv...

Daniel S. Levine @dslevine.bsky.social · Aug 1

Here's what you may have missed in July from The Bio Report, RARECast, Life Sciences D'n'A, and MitoCast podcasts.

www.linkedin.com/pulse/new-ap...

New Approach to Male Contraception, A Rare Disease Youth Movement, and Why Astronauts May Provide the Key to Mitochondrial Health

Here's what you may have missed in July from The Bio Report, RARECast, Life Sciences D'n'A, and MitoCast podcasts. If you enjoy our content, be sure to like, comment, and subscribe on your preferred p...

www.linkedin.com

1

Daniel S. Levine @dslevine.bsky.social · Jul 31

David B. Goldstein, founder and CEO of Actio Biosciences, Inc., discusses the company’s rare-to-common business model, how it identifies the indications it will pursue, and why pricing may represent a challenge. @globalgenes.bsky.social #RARECast

globalgenes.org/raredaily/a-...

A Rare-to-Common-Business Model

David Goldstein, founder and CEO of Actio Biosciences, discusses the company’s rare-to-common business model, how it identifies the indications it will pursue, and why pricing represents a challenge f...

globalgenes.org

1

Daniel S. Levine @dslevine.bsky.social · Jul 30

Juho Jalkanen, founder and CEO of Faron, discusses how the tumor microenvironment can suppress macrophages, how the company’s macrophage checkpoint inhibitor works, and the challenges a Finland-based company faces accessing the capital markets.
thebioreport.podbean.com/e/outsmartin...

1